دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal Cancer.
Ko, Andrew H. MD 1,2,
doi : 10.1200/JCO.23.00221
Volume 41(18) pgs. 3275-3457 June 20, 2023
JCO Flashback: Predictive Value of KRAS Mutations on the Outcomes of Panitumumab Monotherapy in Colorectal Cancer.
doi : 10.1200/JCO.23.00490
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer.
Amado, Rafael G.; Wolf, Michael; Peeters, Marc; Van Cutsem, Eric; Siena, Salvatore; Freeman, Daniel J.; Juan, Todd; Sikorski, Robert; Suggs, Sid; Radinsky, Robert; Patterson, Scott D.; Chang, David D.
doi : 10.1200/JCO.22.02758
Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC).
Peritumoral Lidocaine Injection: A Low-Cost, Easily Implemented Intervention to Improve Outcomes in Early-Stage Breast Cancer.
Higgins, Tessa BA 1,2; Mittendorf, Elizabeth A. MD, PhD, MHCM 1,2,3,,
doi : 10.1200/JCO.23.00418
Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary?.
Antonarakis, Emmanuel S. MD 1,,; Abida, Wassim MD, PhD 2,
doi : 10.1200/JCO.23.00270
Acting on Actionable Mutations in Metastatic Prostate Cancer.
Marshall, Catherine H. MD, MPH 1,,
doi : 10.1200/JCO.23.00350
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?.
Dottorini, Lorenzo MD 1; Petrelli, Fausto MD 1,; Ghidini, Antonio MD 2; Rea, Carmen Giusy MD 1; Borgonovo, Karen MD 1; Dognini, Giuseppina MD 1; Parati, Maria Chiara MD 1; Petro, Daniela MD 1; Ghilardi, Mara MD 1; Luciani, Andrea MD 1
doi : 10.1200/JCO.23.00354
Evolving Landscape of Metastatic Cancer Survivorship: Reconsidering Clinical Care, Policy, and Research Priorities for the Modern Era.
Lai-Kwon, Julia MBBS (Hons), MPH 1,2; Heynemann, Sarah MBBS, MBioeth 3,4; Hart, Nicolas H. PhD 5,6,7,8,; Chan, Raymond J. PhD, MAppSc, RN 5; Smith, Thomas J. MD 9,10,; Nekhlyudov, Larissa MD, MPH 11,; Jefford, Michael PhD, MBBS, MPH, MHlthServMt 1,2,12,13,
doi : 10.1200/JCO.22.02212
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
Dy, Grace K. MD 1,,; Govindan, Ramaswamy MD 2,; Velcheti, Vamsidhar MD 3,; Falchook, Gerald S. MD 4,; Italiano, Antoine MD, PhD 5,; Wolf, Jurgen MD, PhD 6,; Sacher, Adrian G. MD 7,; Takahashi, Toshiaki MD, PhD 8,; Ramalingam, Suresh S. MD 9,; Dooms, Christophe MD, PhD 10; Kim, Dong-Wan MD, PhD 11,; Addeo, Alfredo MD, PhD 12,; Desai, Jayesh MBBS, FRACP 13,; Schuler, Martin MD 14,; Tomasini, Pascale MD 15,; Hong, David S. MD 16,; Lito, Piro MD, PhD 17,; Tran, Qui PhD 18,; Jones, Simon PhD 18,; Anderson, Abraham PhD 18,; Hindoyan, Antreas PhD 18,; Snyder, Wendy PhD 18,; Skoulidis, Ferdinandos MD, PhD, MRCP 16,; Li, Bob T. MD, PhD, MPH 17,
doi : 10.1200/JCO.22.02524
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer.
Badwe, Rajendra A. MS 1,; Parmar, Vani MS, DNB 1; Nair, Nita MS, DNB, MCh, MRCS 1; Joshi, Shalaka MS 1; Hawaldar, Rohini BSc, DCM 1; Pawar, Suraj MS, FICS, FAIS, FMAS, FIAGES 2; Kadayaprath, Geeta MS, FRCS 3; Borthakur, Bibhuti B. MS 4; Rao Thammineedi, Subramanyeshwar MS, MCh, FMAS 5; Pandya, Shashank MBBS, MS, MCh 6; Balasubramanian, Satheesan MS, DNB, MCh 7; Chitale, Priyadarshan V. MBBS, MS 8; Neve, Rakesh MBBS, MS, DNB 9; Harris, Caleb MS, MCh 10; Srivastava, Anurag PhD, MPH, MS, FRCS 11; Siddique, Shabina MSc 1; Vanmali, Vaibhav J. BCom, ADCSSAA, PGDCR 1; Dewade, Ashwini MSc 1; Gaikwad, Varsha MSc 1; Gupta, Sudeep MBBS, MD, DM 1,
doi : 10.1200/JCO.22.01966
Preventing metastases by using perioperative interventions has not been adequately explored. Local anesthesia blocks voltage-gated sodium channels and thereby prevents activation of prometastatic pathways.
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Iwase, Takuji MD 1,2,; Saji, Shigehira MD, PhD 3,; Iijima, Kotaro MD, PhD 1; Higaki, Kenji MD, PhD 4; Ohtani, Shoichiro MD, PhD 4,; Sato, Yasuyuki MD 5; Hozumi, Yasuo MD, PhD 6,; Hasegawa, Yoshie MD 7; Yanagita, Yasuhiro MD 8; Takei, Hiroyuki MD, PhD 9,; Tanaka, Maki MD, PhD 10; Masuoka, Hideji MD, PhD 11; Tanabe, Masahiko MD, PhD 1; Egawa, Chiyomi MD, PhD 12; Komoike, Yoshifumi MD, PhD 13; Nakamura, Toshitaka MD, PhD 14; Ohtsu, Hiroshi MS 15; Mukai, Hirofumi MD, PhD 16,
doi : 10.1200/JCO.22.00577
Treatment with an aromatase inhibitor for 5 years is the standard treatment for postmenopausal hormone receptor-positive breast cancer. We investigated the effects of extending this treatment to 10 years on disease-free survival (DFS).
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi, Kim N. MD 1,,; Rathkopf, Dana MD 2,; Smith, Matthew R. MD 3,; Efstathiou, Eleni MD 4,; Attard, Gerhardt MD 5,; Olmos, David MD 6,; Lee, Ji Youl MD 7; Small, Eric J. MD 8; Pereira de Santana Gomes, Andrea J. MD 9; Roubaud, Guilhem MD 10,; Saad, Marniza MD 11,; Zurawski, Bogdan MD 12,; Sakalo, Valerii MD 13; Mason, Gary E. MD 14,; Francis, Peter MD 15,; Wang, George MS, MAS 14,; Wu, Daphne PhD 16,;
doi : 10.1200/JCO.22.01649
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naive mCRPC when combined with androgen receptor signaling inhibition.
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Morris, Michael J. MD 1,,; Heller, Glenn PhD 2; Hillman, David W. MS 3; Bobek, Olivia MS 3,; Ryan, Charles MD 4,; Antonarakis, Emmanuel S. MD 4,; Bryce, Alan H. MD 5,; Hahn, Olwen MD 6,; Beltran, Himisha MD 7,; Armstrong, Andrew J. MD 8,; Schwartz, Lawrence MD 9,; Lewis, Lionel D. MD, MBBCh, MA 10,; Beumer, Jan H. PhD, PharmD 11,; Langevin, Brooke PharmD 12; McGary, Eric C. MD, PhD 13; Mehan, Paul T. MD 14; Goldkorn, Amir MD 15,; Roth, Bruce J. MD 16,; Xiao, Han MD 1; Watt, Colleen BS 17; Taplin, Mary-Ellen MD 7,; Halabi, Susan PhD 18,; Small, Eric J. MD 19,
doi : 10.1200/JCO.22.02394
Enzalutamide and abiraterone both target androgen receptor signaling but via different mechanisms. The mechanism of action of one drug may counteract the resistance pathways of the other.
Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study.
Park, Joo-Hyun MD, PhD 1,2; Hong, Jung Yong MD, PhD 2,3,,; Shen, Jay J. PhD 2; Han, Kyungdo PhD 4; Park, Joon Oh MD, PhD 3,; Park, Young Suk MD, PhD 3; Lim, Ho Yeong MD, PhD 3,
doi : 10.1200/JCO.22.01740
Although the incidence of young-onset digestive tract cancers is increasing worldwide, their risk factors remain largely unknown. We investigated the association between nonalcoholic fatty liver disease (NAFLD) and young-onset digestive tract cancers.
Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group.
Warren, Katherine E. MD 1,,; Vezina, Gilbert MD 2; Krailo, Mark PhD 3,; Springer, Linda BS 4; Buxton, Allen PhD 5; Peer, Cody J. PhD, BS 6; Figg, William D. PharmD 6,; William-Hughes, Chris BS 4; Kessel, Sandy PhD 7; Fouladi, Maryam MD 8,; Gajjar, Amar MD 9,; Bowers, Daniel MD 10
doi : 10.1200/JCO.22.01777
Children with low-grade glioma often require long-term therapy and suffer from treatment morbidity. Although targeted agents are promising, tumor targets often encompass normal developmental pathways and long-term effects of inhibition are unknown.
GET FIT: A Randomized Clinical Trial of Tai Ji Quan Versus Strength Training for Fall Prevention After Chemotherapy in Older, Postmenopausal Women Cancer Survivors.
Winters-Stone, Kerri M. PhD, FACSM 1,2,,; Horak, Fay PhD 3,; Dieckmann, Nathan F. PhD 4; Luoh, Shiuh-Wen MD, PhD 1,5; Eckstrom, Elizabeth MD, MPH 6; Stoyles, Sydnee A. MBST 4; Roeland, Eric J. MD 2,; Li, Fuzhong PhD 7
doi : 10.1200/JCO.22.01519
To compare the efficacy of tai ji quan versus strength training to prevent falls after chemotherapy in older, postmenopaual women.
Adoptive Cell Therapy for Nonhematologic Solid Tumors.
Olson, Daniel J. MD 1,2,; Odunsi, Kunle MD, PhD 2,3,,
doi : 10.1200/JCO.22.01618
AB The long-term benefits demonstrated by immunotherapy in select tumors have failed to generalize to most nonhematologic solid tumors. Adoptive cell therapy (ACT)-a treatment on the basis of the isolation and engineering of living T cells and other immune cells-has shown early clinical advances.
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents.
Moreno, Lucas MD, PhD 1,; DuBois, Steven G. MD, MS 2,; Glade Bender, Julia MD 3,; Mauguen, Audrey PhD 3,; Bird, Nick MSc 4; Buenger, Vickie PhD 5; Casanova, Michela MD 6,; Doz, Francois MD 7,8,; Fox, Elizabeth MD 9; Gore, Lia MD 10,11,; Hawkins, Douglas S. MD 12,13,; Izraeli, Shai MD 14,15,; Jones, David T.W. PhD 16,19,; Kearns, Pamela R. MB ChB, PhD 20,21,; Molenaar, Jan J. MD, PhD 22,23; Nysom, Karsten MD, PhD 24,; Pfister, Stefan MD 16,17,18,; Reaman, Gregory MD 25; Smith, Malcolm MD, PhD 26; Weigel, Brenda MD, MSc 27; Vassal, Gilles MD, PhD 28,29,30,; Zwaan, Christian Michel MD, PhD 22,31,; Paoletti, Xavier PhD 32,; Iasonos, Alexia PhD 3,; Pearson, Andrew D.J. MBBS, MD, DCH 28,29,
doi : 10.1200/JCO.22.02430
There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious than monotherapy for most diseases and may overcome resistance mechanisms and increase synergy.
Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Burstein, Harold J. MD, PhD 1,; DeMichele, Angela MD 2,; Somerfield, Mark R. PhD 3; Henry, N. Lynn MD, PhD 4,; for the Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels
doi : 10.1200/JCO.23.00638
AB ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual.
Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update.
Andersen, Barbara L. PhD 1,a; Lacchetti, Christina MHSc 2; Ashing, Kimlin PhD 3,; Berek, Jonathan S. MD, MMS 4,; Berman, Barry S. MD, MS 5,; Bolte, Sage PhD 6; Dizon, Don S. MD 7,; Given, Barbara PhD, RN 8,; Nekhlyudov, Larissa MD, MPH 9,10,; Pirl, William MD, MPH 10,; Stanton, Annette L. PhD 11; Rowland, Julia H. PhD 12
doi : 10.1200/JCO.23.00293
To update the American Society of Clinical Oncology guideline on the management of anxiety and depression in adult cancer survivors. METHODS: A multidisciplinary expert panel convened to update the guideline.
US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.
Royce, Melanie MD, PhD; Mulkey, Flora MS; Osgood, Christy MD; Bloomquist, Erik PhD; Amiri-Kordestani, Laleh MD
doi : 10.1200/JCO.23.00615
